# PATENT COGPERATION TREATY REC'D 29 NOV 2000

### PCT

WIPO PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| Applicant's           | or an           | ent's file reference  | T  | · · · · · · · · · · · · · · · · · · · |                 |   |  |
|-----------------------|-----------------|---|--|---------------------------------------|-----------------|---|--|
| 3206-17               | _               |   | FOR FURTHER AC   | TION                                  |                 | ation of Transmittal of Internatio<br>Examination Report (Form PC       |  |
| Internation           | al app          | lication No.  | International filing date (d   | lay/month                             | n/year)         | Priority date (day/month/year)  | )  |
| PCT/CA                |                 |   | 13/03/2000   | •                                     | ,               | 12/03/1999  |  |
| Internation<br>C07C32 |                 | ent Classification (IPC) or na  | tional classification and IPC  | ;                                     |                 |   |  |
|                       | SEA             | RCH AND DEVELOPM  | ENT LIMITED PARTI  | NERSH                                 | IP              |   |  |
| 1. This i             | ntern<br>s tran | ational preliminary exami<br>smitted to the applicant a   | nation report has been p   | orepared                              | by this Inte    | rnational Preliminary Exami   | ning Authority   |
| 2. This               | REPO            | ORT consists of a total of  | 4 sheets, including this   | cover sl                              | heet.           |   |  |
| b<br>(:               | een a<br>see F  | eport is also accompanied<br>amended and are the bas<br>tule 70.16 and Section 60<br>exes consist of a total of | is for this report and/or and/or of the Administrative   | sheets c                              | ontaining red   | n, claims and/or drawings w<br>ctifications made before this<br>e PCT). | hich have<br>Authority   |
|                       | ar              | contains indications rela   | ting to the following item   | ıs:                                   |                 |   |  |
| 1                     | N<br>N          | Basis of the report   |  |                                       |                 |   |  |
| 11                    |                 |   | and and the second states are as a second state of the second states are a second state of the second state of the second states are a second state of the second states ar |                                       |                 |   |  |
| 111                   |                 |   |  | elty, inv                             | entive step a   | and industrial applicability  |  |
| V                     | ⊠               | Lack of unity of invention<br>Reasoned statement un<br>citations and explanation                                | nder Article 35(2) with re   | gard to                               | novelty, inve   | ntive step or industrial appli  | cability;  |
| VI                    |                 |   | <del>-</del>   | ment                                  |                 |   |  |
| VII                   |                 |   | _  |                                       |                 |   |  |
| VIII                  |                 | Certain observations on   |  | ation                                 |                 |   |  |
| <u> </u>              |                 |   |  |                                       |                 |   |  |
| Date of sub           | missio          | on of the demand  |  | Date of o                             | completion of t | his report  |  |
| 11/10/20              | 00              |   |  | 27.11.20                              | 000             |   |  |
|                       |                 | g address of the international ining authority:   |  | Authoriz                              | ed officer      |   | SUSCO LECHES MATCHINE.   |
| <u>)</u>              | Euro<br>D-80    | ppean Patent Office<br>0298 Munich<br>+49 89 2399 - 0 Tx: 523656  | enmu d   | Sen, A                                |                 |   | TES OFFICE STATES  |
|                       |                 | +49 89 2399 - 4465  | Op.110 G   | Telephor                              | ne No. +49 89   | 2399 8328   | ** THE THE PERSON THE PROPERTY OF THE PERSON |

International application No. PCT/CA00/00266

| I. Basis of the | report |
|-----------------|--------|
|-----------------|--------|

| 1. | res <sub>l</sub><br>the | oonse to an invitatio   | rawn on the basis of (substitute sheets which have been furnished to the receiving Office on under Article 14 are referred to in this report as "originally filed" and are not annexed to not contain amendments (Rules 70.16 and 70.17).): |  |  |  |  |  |
|----|-------------------------|---|---|--|--|--|--|--|
|    | 1-1                     | 5   | as originally filed   |  |  |  |  |  |
|    | Cla                     | ims, No.:   |   |  |  |  |  |  |
|    | 1-37                    | 7   | as originally filed   |  |  |  |  |  |
|    | Dra                     | wings, sheets:  |   |  |  |  |  |  |
|    | 1-17                    | 7   | as originally filed   |  |  |  |  |  |
|    |                         |   |   |  |  |  |  |  |
| 2. | With<br>lang            | n regard to the <b>lang</b><br>Juage in which the i                   | uage, all the elements marked above were available or furnished to this Authority in the nternational application was filed, unless otherwise indicated under this item.  |  |  |  |  |  |
|    | The                     | se elements were a  | available or furnished to this Authority in the following language: , which is:   |  |  |  |  |  |
|    |                         | the language of a t   | translation furnished for the purposes of the international search (under Rule 23.1(b)).  |  |  |  |  |  |
|    |                         | the language of pu  | blication of the international application (under Rule 48.3(b)).  |  |  |  |  |  |
|    |                         | the language of a t 55.2 and/or 55.3).                                | ranslation furnished for the purposes of international preliminary examination (under Rule  |  |  |  |  |  |
| 3. | With<br>inter           | n regard to any <b>nuc</b><br>rnational preliminar                    | leotide and/or amino acid sequence disclosed in the international application, the y examination was carried out on the basis of the sequence listing:  |  |  |  |  |  |
|    |                         | contained in the int  | ternational application in written form.  |  |  |  |  |  |
|    |                         | filed together with t   | the international application in computer readable form.  |  |  |  |  |  |
|    |                         | furnished subsequ   | ently to this Authority in written form.  |  |  |  |  |  |
|    |                         | ☐ furnished subsequently to this Authority in computer readable form. |   |  |  |  |  |  |
|    |                         |   | ent that the subsequently furnished written sequence listing does not go beyond the disclosure in onal application as filed has been furnished.   |  |  |  |  |  |
|    |                         | The statement that listing has been fur                               | the information recorded in computer readable form is identical to the written sequence rnished.  |  |  |  |  |  |
| 4. | The                     | amendments have   | resulted in the cancellation of:  |  |  |  |  |  |
|    |                         | the description,  | pages:  |  |  |  |  |  |
|    |                         | the claims,   | Nos.:   |  |  |  |  |  |
|    |                         |   |   |  |  |  |  |  |

International application No. PCT/CA00/00266

|    |   | the drawings,  | sheets:                               |   |  |  |  |  |  |  |
|----|---|--|---------------------------------------|---|--|--|--|--|--|--|
| 5. | ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)): |  |                                       |   |  |  |  |  |  |  |
|    |   | (Any replacement she report.)                          | eet conta                             | ining such                              | n amendments must be referred to under item 1 and annexed to this                        |  |  |  |  |  |
| 6. | Add   | litional observations, if                              | necessa                               | ry:                                     |  |  |  |  |  |  |
|    | _   |  |                                       |   |  |  |  |  |  |  |
| V. | rita:   | isoned statement und<br>tions and explanatior          | ler Articl<br>is suppo                | e 35(2) w<br>orting suc                 | rith regard to novelty, inventive step or industrial applicability;                      |  |  |  |  |  |
|    | cita  | isoned statement und<br>tions and explanation<br>ement | ler Articl<br>ns suppo                | e 35(2) w<br>orting suc                 | rith regard to novelty, inventive step or industrial applicability; ch statement         |  |  |  |  |  |
|    | State   | tions and explanation                                  | ler Articl<br>ns suppo<br>Yes:<br>No: | e 35(2) worting suc<br>Claims<br>Claims | rith regard to novelty, inventive step or industrial applicability; ch statement  - 1-37 |  |  |  |  |  |
| 1. | State   | tions and explanation                                  | n <b>s suppo</b><br>Yes:              | orting suc<br>Claims                    | ch statement   |  |  |  |  |  |

2. Citations and explanations see separate sheet

## INTERNATIONAL PRELIMINARY International application No. PCT/CA00/00266 EXAMINATION REPORT - SEPARATE SHEET

D1: US-A-5 773 476 D2: WO 94 26260 A

D3: JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, (1991), pages 1896-1907

### SECTION V:

The subject-matter of the application relates to benzylidene malononitrile compounds of general formula I which are described in connection with " an unexpectedly improved efficacy for treatment of cell proliferative diseases", see page 4, lines 6-9. Accordingly, it is shown that the compounds described give complete suppression of proliferation of human acute lymphoblastic leukemia cells without significantly affecting normal bone marrow cells, see page 12, Example 2 to page 15, Example 6; and see also the Figures, e.g. Figure 7/17 or Figure 17/17.


Document D1 cited on page 1, describes a number of benzylidene malononitrile derivatives which however differ from the present compounds with regard to the substitution on the phenyl ring: in D1 a  $\underline{3'}$ ,  $\underline{5'}$ -tert.-butyl-4'-OH- substitution, whereas in the present application a  $\underline{3'}$ -OR<sub>1</sub>-4'-OH- $\underline{5'}$ -methylene-SR<sub>2</sub> substitution.

Similar differences in the definition of the substituents on the phenyl ring are found in D2, which describes a simple 3',4'-dihydroxy substitution on the phenyl ring, and in D3, see page 7, lines 11-18. Moreover the compounds of D3 differ in the length and substitution of the side chain: in D3  $-C(R_{11})=C(CN)R_{12}$ , whereas in the present application  $-CH=C(CN)-C(=O)-NH-CHR_3R_4$ .

For the assessment of the present claims 23-37 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.








(PCT Article 36 and Rule 70)


| Applicant's or agent's file reference   |  | Coo Natification of Transmitted of the  |
|---|--|---|
| 3206-176/PAR  | FOR FURTHER ACTION   | See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)                     |
| International application No.   | International filing date (day/month   | /year) Priority date (day/month/year)   |
| PCT/CA00/00266  | 13/03/2000   | 12/03/1999  |
| International Patent Classification (IPC) or na C07C323/60  Applicant                           |  | <b>'</b>  |
| HSC RESEARCH AND DEVELOPM   | MENT LIMITED PARTNERSHI  | P   |
| This international preliminary examinand is transmitted to the applicant a                      | ination report has been prepared according to Article 36.  | by this International Preliminary Examining Authority   |
| 2. This REPORT consists of a total of   | 4 sheets, including this cover sh  | eet.  |
| been amended and are the bas  | is for this report and/or sheets co<br>Of of the Administrative Instruction  | e description, claims and/or drawings which have ontaining rectifications made before this Authority ns under the PCT). |
|   |  |   |
| IV  | pinion with regard to novelty, invented in the control of the cont | entive step and industrial applicability  ovelty, inventive step or industrial applicability;                           |
| Date of submission of the demand  | Date of co   | mpletion of this report   |
| 11/10/2000  | 27.11.200  | 0   |
| Name and mailing address of the international preliminary examining authority:                  | Authorized   | d officer   |
| European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 6 Fax: +49 89 2399 - 4465 | ·  | No. +49 89 2399 8328  |






### I. Basis of the report

| 1  | re:<br>the  | sponse to an invitati   | Irawn on the basis of (substitute sheets which have been furnished to the receiving Office in on under Article 14 are referred to in this report as "originally filed" and are not annexed to lo not contain amendments (Rules 70.16 and 70.17).): |  |  |  |  |
|----|-------------|---|--|--|--|--|--|
|    | 1-          | 15  | as originally filed  |  |  |  |  |
|    | Cla         | aims, No.:  |  |  |  |  |  |
|    | 1-3         | 37  | as originally filed  |  |  |  |  |
|    | Dra         | awings, sheets:   |  |  |  |  |  |
|    | 1-1         | 17  | as originally filed  |  |  |  |  |
|    |             |   |  |  |  |  |  |
| 2. | Wit<br>lan  | th regard to the <b>lang</b><br>guage in which the i  | uage, all the elements marked above were available or furnished to this Authority in the nternational application was filed, unless otherwise indicated under this item.   |  |  |  |  |
|    | The         | ese elements were a   | available or furnished to this Authority in the following language: , which is:  |  |  |  |  |
|    |             | the language of a   | translation furnished for the purposes of the international search (under Rule 23.1(b)).   |  |  |  |  |
|    |             |   | blication of the international application (under Rule 48.3(b)).   |  |  |  |  |
|    |             |   | ranslation furnished for the purposes of international preliminary examination (under Rule   |  |  |  |  |
| 3. | Wit<br>inte | h regard to any <b>nuc</b><br>ernational preliminar   | leotide and/or amino acid sequence disclosed in the international application, the yexamination was carried out on the basis of the sequence listing:  |  |  |  |  |
|    |             | contained in the in   | ternational application in written form.   |  |  |  |  |
|    |             | filed together with   | the international application in computer readable form.   |  |  |  |  |
|    |             | furnished subsequ   | ently to this Authority in written form.   |  |  |  |  |
|    |             | furnished subsequ   | ently to this Authority in computer readable form.   |  |  |  |  |
|    |             | The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in<br>the international application as filed has been furnished. |  |  |  |  |  |
|    |             | The statement that listing has been fur   | the information recorded in computer readable form is identical to the written sequence nished.  |  |  |  |  |
| 4. | The         | amendments have   | resulted in the cancellation of:   |  |  |  |  |
|    |             | the description,  | pages:   |  |  |  |  |
|    |             | the claims,   | Nos.:  |  |  |  |  |








|    |             | the drawings,                                | sheets:                |                          | •  |
|----|-------------|--|------------------------|--------------------------|--|
| 5. |             | This report has been considered to go bey    | establishond the d     | ed as if (s<br>isclosure | some of) the amendments had not been made, since they have been as filed (Rule 70.2(c)): |
|    |             | (Any replacement sho<br>report.)             | eet contai             | ining such               | h amendments must be referred to under item 1 and annexed to this                        |
| 6. | Add         | itional observations, if                     | necessai               | ry:                      |  |
| V. | Rea<br>cita | soned statement und<br>tions and explanation | der Articl<br>ns suppo | e 35(2) w<br>orting suc  | vith regard to novelty, inventive step or industrial applicability; ch statement         |
| 1. | Stat        | ement  |                        |                          |  |
|    | Nov         | elty (N)                                     | Yes:<br>No:            | Claims<br>Claims         | 1-37   |
|    | Inve        | ntive step (IS)                              | Yes:<br>No:            | Claims<br>Claims         | 1-37   |
|    | Indu        | strial applicability (IA)                    | Yes:<br>No:            | Claims<br>Claims         | 1-37   |

2. Citations and explanations see separate sheet



D1: US-A-5 773 476 D2: WO 94 26260 A


D3: JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, (1991), pages 1896-1907

### SECTION V:

The subject-matter of the application relates to benzylidene malononitrile compounds of general formula I which are described in connection with " an unexpectedly improved efficacy for treatment of cell proliferative diseases", see page 4, lines 6-9. Accordingly, it is shown that the compounds described give complete suppression of proliferation of human acute lymphoblastic leukemia cells without significantly affecting normal bone marrow cells, see page 12, Example 2 to page 15, Example 6; and see also the Figures, e.g. Figure 7/17 or Figure 17/17.

Document D1 cited on page 1, describes a number of benzylidene malononitrile derivatives which however differ from the present compounds with regard to the substitution on the phenyl ring: in D1 a 3', 5'-tert.-butyl-4'-OH- substitution, whereas in the present application a 3'-OR<sub>1</sub>-4'-OH-5'-methylene-SR<sub>2</sub> substitution. Similar differences in the definition of the substituents on the phenyl ring are found in D2, which describes a simple 3',4'-dihydroxy substitution on the phenyl ring, and in D3, see page 7, lines 11-18. Moreover the compounds of D3 differ in the length and substitution of the side chain: in D3 -C(R<sub>11</sub>)=C(CN)R<sub>12</sub>, whereas in the present application -CH=C(CN)-C(=O)-NH-CHR<sub>3</sub>R<sub>4</sub>.

For the assessment of the present claims 23-37 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.




# PCT COOPERATION TREATY

### **INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference FOR FURTHER see Notification of Transmittal of International Search Repo (Form PCT/ISA/220) as well as, where applicable, item 5 be  |   |   |  |  |  |
|--|---|---|--|--|--|
| 3206-176/PAR International application No.   | International application No. International filing date (day/month/year) (Earliest) Priority Date (day/month/year)                                    |   |  |  |  |
| ,,   |   |   |  |  |  |
| PCT/CA 00/00266  | 13/03/2000  | 12/03/1999  |  |  |  |
| Applicant HSC RESEARCH AND DEVELOPMI   | ENT LIMITED PARTNERSHIP   |   |  |  |  |
| according to Article 18. A copy is being tra  This international Search Report consists  |   |   |  |  |  |
| Basis of the report  |   |   |  |  |  |
| a. With regard to the language, the i  | nternational search was carried out on the basess otherwise indicated under this item.  | sis of the international application in the   |  |  |  |
| the International search was Authority (Rule 23.1(b)).   | as carried out on the basis of a translation of ti  | ne international application furnished to this  |  |  |  |
| b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  turnished subsequently to this Authority in written form.  turnished subsequently to this Authority in computer readible form.  the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished  Certain claims were found unsearchable (See Box I).  Unity of invention is lacking (see Box II). |   |   |  |  |  |
| 4. With regard to the title,   |   |   |  |  |  |
| the text is approved as sui  | omitted by the applicant.   |   |  |  |  |
|  | ned by this Authority to read as follows:   |   |  |  |  |
| 6. The figure of the drawings to be publicated by the applicate fallowings to be applicant fallowings.   | ned, according to Rule 38.2(b), by this Authorit<br>date of mailing of this international search rep<br>shed with the abstract is Figure No.<br>sant. | y as it appears in Box III. The applicant may, ort, submit comments to this Authority.  1  None of the figures. |  |  |  |



### INTERNATIONAL SEARCH REPORT

International Application No

A 00/00266

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C323/60 C07D277/74 A61K31/277 A61K31/428 A61P35/02

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{C07C} & \mbox{C07D} & \mbox{A61K} & \mbox{A61P} \\ \end{array}$ 

C. DOCUMENTS CONSIDERED TO BE RELEVANT


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | US 5 773 476 A (A. GAZIT, ET AL.) 30 June 1998 (1998-06-30) cited in the application the whole document  | 1,12,23               |
| Α          | A. GAZIT, ET AL.: "Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases" JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 6, 1 June 1991 (1991-06-01), pages 1896-1907, XP000472938 American Chemical Society, Washington, DC, US ISSN: 0022-2623 table III | 1,12,23               |

| X Further documents are listed in the continuation of box C.   | Patent family members are listed in annex.  |
|--|---|
| <ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filling date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> </ul> | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family |
| Date of the actual completion of the international search  31 May 2000   | Date of mailing of the International search report  13/06/2000  |
| Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,  Fax: (+31-70) 340-3016   | Authorized officer  English, R  |


-/--



### **INTERNATIONAL SEARCH REPORT**

International Application No
PC 00/00266

|            | tion) DOCUMENTS CONSIDERED BE RELEVANT   |                       |
|------------|--|-----------------------|
| Category ° | Citation of document, with indication, where appropriate, of the relevant passages           | Relevant to claim No. |
|            | WO 94 26260 A (YISSUM RESEARCH<br>DEVELOPMENT) 24 November 1994 (1994-11-24)<br>claims 1,2,4 | 1,12,23               |
|            |  |                       |
|            |  |                       |
|            | · .  |                       |
|            |  |                       |
|            |  |                       |
|            |  |                       |
|            |  |                       |
|            |  |                       |




### **INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No
PC A 00/00266

| Patent document<br>cited in search repor | t | Publication date |                | atent family<br>member(s)           | Publication date                       |  |
|--|---|------------------|----------------|-------------------------------------|--|--|
| US 5773476                               | A | 30-06-1998       | US<br>AU<br>WO | 5789427 A<br>2096895 A<br>9524190 A | 04-08-1998<br>25-09-1995<br>14-09-1995 |  |
| WO 9426260                               | Α | 24-11-1994       | AU<br>ZA       | 6910994 A<br>9403305 A              | 12-12-1994<br>30-01-1995               |  |



### PA:FINT COOPERATION TREATY

### From the INTERNATIONAL BUREAU

### **PCT**

### **NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

ROIFMAN, Chaim, M. et al

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202

Date of mailing (day/month/year)

O7 November 2000 (07.11.00)

ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

International application No.
PCT/CA00/00266

International filing date (day/month/year)
13 March 2000 (13.03.00)

Applicant

Priority date (day/month/year)
12 March 1999 (12.03.99)

Applicant

1. The designated Office is hereby notified of its election made:

| X | in the demand filed with the International Preliminary Examining Authority on:
| 11 October 2000 (11.10.00)
| in a notice effecting later election filed with the International Bureau on:
| 2. The election | X | was | was not | was 2.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

**Charlotte ENGER** 

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35